Who Paid My Doc
David Doriguzzi
Physician Assistant, Medical Lancaster, CA Physician Assistant
NPI 1730195728 CMS profile 11198293
44725 10Th St W, Ste 210, Lancaster, CA 93534
General payments
$165,568
Research payments
$1,883
Ownership & investment interest
$0
Research they led as principal investigator
$348,681
Through program year 2025, David Doriguzzi of Lancaster, CA is reported in the CMS Open Payments database as having received $165,568 across 777 general payments and $1,883 in research payments paid to them. Separately, studies naming them as principal investigator received $348,681 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $53,472 | 240 | |
| 2024 | General | $32,309 | 158 | |
| 2023 | General | $31,205 | 159 | |
| 2022 | General | $28,136 | 134 | |
| 2022 | Research | $1,883 | 8 | |
| 2021 | General | $20,446 | 86 |
Beside peers
- David Doriguzzi
- Physician Assistant, Medical median
- Middle half of Physician Assistant, Medical
- National median
In program year 2025, general payments to David Doriguzzi were reported at $53,472. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.
Show as a table
| Year | David Doriguzzi | Physician Assistant, Medical median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $19–$193 | $163 |
| 2020 | $0 | $20 | $14–$64 | $114 |
| 2021 | $20,446 | $156 | $41–$563 | $132 |
| 2022 | $28,136 | $185 | $55–$649 | $149 |
| 2023 | $31,205 | $199 | $58–$717 | $160 |
| 2024 | $32,309 | $206 | $62–$740 | $164 |
| 2025 | $53,472 | $214 | $62–$755 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 161 drugsPart D claims
8,458
Drug cost
$3,097,399
Branded share of claims
38.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Korlym Mifepristone | Brand | 13 | $688,741 | |
| Ozempic Semaglutide | Brand | 429 | $500,154 | |
| Rybelsus Semaglutide | Brand | 187 | $228,204 | |
| Jardiance Empagliflozin | Brand | 193 | $197,788 | |
| Farxiga Dapagliflozin Propanediol | Brand | 138 | $140,014 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 92 | $118,070 | |
| Kerendia Finerenone | Brand | 101 | $116,513 | |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 130 | $114,645 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 107 | $95,725 | |
| Trulicity Dulaglutide | Brand | 52 | $60,941 |
The 10 drugs with the highest cost, of 161 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 17 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Ozempic |
|
$3,011 | 429 | — |
| RYBELSUS |
|
$2,023 | 187 | — |
| Korlym |
|
$464 | 13 | — |
| RECORLEV |
|
$417 | — | — |
| Kerendia |
|
$230 | 101 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 17 in the dashboard with a free accountRecords
785 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant, Medical in California
Nicola Lowrey
Physician Assistant, Medical · Orange, CA
Justin Love
Physician Assistant, Medical · Loma Linda, CA
Alison Gracom
Physician Assistant, Medical · Irvine, CA
Jeffrey Bonnaud
Physician Assistant, Medical · Los Angeles, CA
Ana Torres
Physician Assistant, Medical · Laguna Beach, CA
Heather Parlett
Physician Assistant, Medical · Redlands, CA
Related records
Physician Assistant, Medical in California
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant, Medical
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.